These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11734111)

  • 41. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
    Basso AD; Kirschmeier P; Bishop WR
    J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
    Cox AD; Der CJ
    Biochim Biophys Acta; 1997 Aug; 1333(1):F51-71. PubMed ID: 9294018
    [No Abstract]   [Full Text] [Related]  

  • 43. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
    Lancet JE; Karp JE
    Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
    Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
    Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability.
    Falugi C; Trombino S; Granone P; Margaritora S; Russo P
    Curr Cancer Drug Targets; 2003 Apr; 3(2):109-18. PubMed ID: 12678714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
    Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
    Dempke WC
    Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
    Sebti SM
    Cancer Cell; 2005 Apr; 7(4):297-300. PubMed ID: 15837619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farnesyltransferase inhibitor as anticancer agent.
    Agrawal AG; Somani RR
    Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity.
    Dinsmore CJ; Bell IM
    Curr Top Med Chem; 2003; 3(10):1075-93. PubMed ID: 12769709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
    Pan J; She M; Xu ZX; Sun L; Yeung SC
    Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protein farnesyltransferase inhibitors.
    Head JE; Johnston SR
    Expert Opin Emerg Drugs; 2003 May; 8(1):163-78. PubMed ID: 14610919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.